Aerodrom "Nikola Tesla" objavio je poslovne rezultate za proteklu godinu u kojoj je došlo do snažnog pada krajnjeg rezultata ove kompanije.

Aerodrom je lani zabeležio poslovni prihod od 6,4 milijarde dinara što je 6,4 odsto više u odnosu na godinu dana ranije. Kako je ranije bilo poznato, Aerodrom je u prošloj godini uslužio 3,4 miliona putnika što je rast od 7,7% na godišnjem nivou.

Poslovna dobit ove kompanije je za pala za pet odsto na 2,15 milijardi dinara dok je krajnji rezultat zabeležio oštru korekciju i iznosio je 727,7 miliona dinara. Pad neto dobiti Aerodroma bio je čak 54%, pre svega usled povećanja ostalih rashoda koji su iznosili 1,8 milijardi dinara (povećanje od 2,4 puta).

Najveći deo pozicije ostalih rashoda odnosi se na nenaplativa potraživanja Aerodroma od strane "Jat"-a koji je najvažniji klijent ove kompanije i učestvuje u njenim prihodima sa više od 40%.

Akcije Aerodroma na Beogradskoj berzi od početka godine beleže rast vrednosti od 9,2%, a po poslednjoj ceni od 489 dinara tržišna kapitalizacija kompanije iznosi 16,8 milijardi dinara (oko 150 mil EUR).

"Galenika" dobija još jednu šansu. Vlada je odlučila da ponovo, drugi put, produži rok do kog zainteresovane kompanije mogu da dostave pismo o namerama. Umesto do ponedeljka, eventualni strateški partneri našeg proizvođača lekova svoju ponudu će moći da prilože do kraja aprila.

Imaju priliku i da posete samu fabrirku i provere dokumentaciju i to do 29. aprila. Međunarodni tender za dostavljanje pisma o namerama za strateško partnerstvo Vlade Srbije je raspisala još 15. januara. Rok za prijavu je bio najpre 18. februar, a rok za dostavljanje pisma o namerama 18. mart. Poziv je zatim prvi put produžen i to do 4. marta i 1. aprila. U petak je odlučeno da se rokovi još jednom prolongiraju i to zato da bi zainteresovani imali dovoljno vremena da obiđu fabriku i pripreme ponudu.

Javni poziv je upućen tako da kompanijama ostavlja mogućnost da same definišu kakav su model saradnje spremne da ponude.

Uslov koji budući kupac treba da ispuni jeste da u farmaceutskom sektoru posluje najmanje poslednjih pet godina, a da je u 2011. ostvario 200 mil EUR poslovnog prihoda.

Nikola Tesla Airport has announced its business results for the previous year in which the final result of this company dropped significantly.

Last year Nikola Tesla Airport reported a business revenue of RSD 6.4 billion, up 6.4 percent from the year before. The airport handled 3.4 million passengers in 2012, up 7.7 percent from 2011.

The company's business profit fell 5 percent to RSD 2.15 billion, whereas its final result amounted to RSD 727.7 million. The airport's net profit dropped as much as 54 percent, primarily due to an increase in other expenditures that reached RSD 1.8 billion (2.4 times bigger expenses than in 2011).

The value of Nikola Tesla Airport shares on the Belgrade Stock Exchange has gone up 9.2 percent since the beginning of this year, and with the latest share price of RSD 489, the company's market cap is at RSD 16.8 billion (about EUR 150 million).

Galenika is getting one more chance. The government has decided to again extend the deadline for all interested companies to submit a letter of intent. Instead of this Monday, the new deadline for prospective strategic partners of the domestic drug manufacturer to submit their bids is end-April. They will also be able to visit the pharmaceutical plant and check the documentation by April 29th.

The Serbian government invited all interested companies on January 15th to submit their letter of intent for strategic partnership with Galenika. The original deadline to apply was February 18th, whereas the deadline to submit a letter of intent was March 18th. However, these deadlines were first extended to March 4th and April 1st, respectively, and then the government made a decision on Friday (29 March 2013) to extend them one more time in order to secure all interested companies enough time to tour the plant and prepare their bids.

The Invitation to Bid leaves open the possibility for companies to define by themselves the model of cooperation they are ready to offer.

The conditions that the future buyer must meet are that it has been operating in the pharmaceutical sector for minimum five last years and that its business revenues in 2011 stood at EUR 200 million.